только для медицинских специалистов

Консультант врача

Электронная медицинская библиотека

Раздел 13 / 24
Страница 12 / 12

Приложение 1. Нежелательные побочные реакции антипсихотиков у пациентов пожилого и старческого возраста

Внимание! Часть функций, например, копирование текста к себе в конспект, озвучивание и т.д. могут быть доступны только в режиме постраничного просмотра.Режим постраничного просмотра
 
 
 
 
 
 
 
 
 
 

  1. Maglione M, Ruelaz Maher A, Hu J et al. Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness Review No. 43. (Prepared by the Southern California Evidence-based Practice Center under Contract No. HHSA290-2007-10062-1.) Rockville, MD, Agency for Healthcare Research and Quality, 2011. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm.
  2. Gill SS, Bronskill SE, Normand SL et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007; 146(11):775–786. https://doi.org/10.7326/0003- 4819-146-11-200706050-00006
  3. Gerhard T, Huybrechts K, Olfson M et al. Comparative mortality risks of antipsychotic medications in community-dwelling older adults. Br J Psychiatry. 2014;205(1):44–51. https://doi.org/10.1192/bjp.bp.112.122499
  4. Huybrechts KF, Rothman KJ, Silliman RA et al. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ. 2014;183(7):411–419. https://doi.org/10.1503/cmaj.101406
  5. Huybrechts KF, Gerhard T, Crystal S et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ. 2012; 344:977. https://doi.org//10.1136/bmj.e977
  6. Ray WA, Chung C, Murray K et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360:225-235. https://doi.org/10.1056/nejmoa0806994
  7. Kales HC, Kim HM, Zivin K et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012;169(1):71–79. https://doi.org//10.1176/appi.ajp.2011.11030347
  8. Maust DT, Kim HM, Seyfried LS et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015;72:438–445. https://doi.org//10.1001/jamapsychiatry.2014.3018
  9. Lopez OL, Becker JT, Chang YF et al. The long-term effects of conventional and atypical ntipsychotics in patients with probable Alzheimer’s disease. Am J Psychiatry. 2013;170(9):1051–1058. https://doi.org/10.1176/appi.ajp.2013.12081046
  10. Rafaniello C, Lombardo F, Ferrajolo C et al. Predictors of mortality in atypical antipsychotic-treated community-dwelling elderly patients with behavioural and psychological symptoms of dementia: a prospective population-based cohort study from Italy. Eur J Clin Pharmacol. 2014;70(2):187–195. https://doi.org//10.1007/s00228-013-1588-3
  11. Buckley N, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Safety. 2000; 23 (3):215–228. https://doi.org//10.2165/00002018-200023030-00004

  1. Burke AD, Tariot PN. Atypical antipsychotics in the elderly: a review of therapeutic trends and clinical outcomes. Expert Opin Pharmacother. 2009;10(15):2407-2414. https://doi.org//10.1517/14656560903200659
  2. https://doi.org//10.1007/s40266-012-0013-4
    Chatterjee S, Chen H, Johnson ML, Aparasu RR. Comparative risk of cerebrovascular adverse events in community-dwelling older adults using risperidone, olanzapine and quetiapine: a multiple propensity scoreadjusted retrospective cohort study. Drugs Aging. 2012;29(10):807– 817.
  3. Gill SS, Rochon PA, Herrmann N et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ. 2005;330(7489):44-52. https://doi.org/10.1136/bmj.38330.470486.8f
  4. Herrmann N, Mamdani M, Lanctôt KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry. 2004;161(6):1113-1115. https://doi.org//10.2165/00023210- 200519020-00001
  5. Liu ME, Tsai SJ, Chang WC et al. Population-based 5-year follow-up study in Taiwan of dementia and risk of stroke. 2013;8(4):761-771. https://doi.org//10.1371/journal.pone.0061771
  6. Sacchetti E, Turrina C, Cesana B, Mazzaglia G. Timing of stroke in elderly people exposed to typical and atypical antipsychotics: a replication cohort study after the paper of Kleijer, et al. J Psychopharmacol. 2009;24(7):1131–1132. https://doi.org//10.1177/0269881109103202
  7. Kleijer BC, van Marum RJ, Egberts AC et al. Risk of cerebrovascular events in elderly users of antipsychotics. J Psychopharmacol. 2009;23(8):909–914. https://doi.org//10.1177/0269881108093583
  8. Imfeld P, Bodmer M, Schuerch M et al. Risk of incident stroke in patients with Alzheimer disease or vascular dementia. Neurology. 2013;81(10):910–919. https://doi.org//10.1212/WNL.0b013e3182a35151
  9. Bолков В.П. Кардиотоксичность фенотиазиновых нейролептиков (обзор литературы). Психиатр. Психофармакотерапия. 2010; 2:41–45. [Volkov V.P. Kardiotoksichnost' fenotiazinovykh neiroleptikov (obzor literatury). Psikhiatr. Psikhofarmakoterapiya. 2010; 2:41– 45. (In Russ.).]
  10. Дробижев М.Ю. Кардиологические аспекты проблемы переносимости и безопасности нейролептика. Психиатр. Психофармакотер. 2004;2:60–68. [Drobizhev M.Yu. Kardiologicheskie aspekty problemy perenosimosti i bezopasnosti neiroleptika. Psikhiatr. Psikhofarmakoter. 2004;2:60–68. (In Russ.).]
  11. Montout C, Casadebaig F, Lagnaoui R et al. Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients. Schizophr. Res. 2002;57:147–156. https://doi.org//10.1016/s0920-9964(01)00325-5
  12. De Hert M, Dekker JM, Wood D et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and European Society of Cardiology (ESC). Eur. Psychiatry. 2009;6(24):412–424. https://doi.org//10.1016/j.eurpsy.2009.01.005
  13. Lawrence D, Kisely S, Pais J. The epidemiology of excess mortality in people with mental illness. Can. J. Psychiatry. 2010;12(55):752–759. https://doi.org//10.1177/070674371005501202
  14. Mortensen PB, Juel K. Mortality and causes of death in schizophrenia in Denmark. Acta Psychiatr. Scand. 1990; 4(8):372–327. https://doi.org/10.1111/j.1600-0447.1990.tb05466.x
  15. Setoguchi S, Wang PS, Brookhart MA et al. Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. J Am Geriatr Soc. 2008;56(9):1644–1650. https://doi.org//10.1111/j.1532-5415.2008.01839.x
  16. Schneeweiss S, Setoguchi S, Brookhart A et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5):627–632. https://doi.org//10.1503/cmaj.070582
  17. Hartigan-Go K, Bateman D, Nyberg G et al. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther. 1996;60 (5):543–553. https://doi.org/10.1016/s0009-9236(96)90150-2
  18. Gelly F, Chambon O, Marie-Cardine M. Long-term clinical experience with clozapine. Encephale. 1997;23(5):385–396.
  19. Pariente A, Fourrier-Reglat A, Ducruet T et al. Antipsychotic use and myocardial infarction in older patients with treated dementia. Arch Intern Med. 2012;172(8):648–653. https://doi.org//10.1001/archinternmed.2012.28
  20. Reilly JG, Ayis SA, Ferrier IN et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000;355(9209):1048-1052. https://doi.org//10.1016/S0140-6736(00)02035-3
  21. Physicians Desk Reference 56th edition. Medical Economics Company Inc, Montvale, NJ; 2002.
  22. Pfizer: Briefing document for ziprasidone HC1 presented at the FDA Psychopharmacological Drugs Advisory Committee; 2000.
  23. Green B. Focus on olanzapine. Curr Med Res Opin. 1999;15(2):79–85. https://doi.org/10.1185/03007999909113367
  24. Polcwiartek C, Sneider B, Graff C, Taylor D, Meyer J, Kanters JK, Nielsen J. The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach. Psychopharmacology. 2015;232(18):3297–3308. https://doi.org/10.1007/s00213-015-4024-9
  25. Hunt N, Stern T. The association between intravenous haloperidol and Torsades de Pointes. Three cases and a literature review. Psychosomatics. 1995;36(6):541–549. https://doi.org/10.1016/s0033-3182(95)71609-7
  26. Sharma N, Rosman H, Padhi I, Tisdale J. Torsades de Pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol. 1998;81(2):238–240. https://doi.org/10.1016/s0002-9149(97)00888-6
  27. Di Salvo T, O'Gara P. Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients. Clin Cardiol. 1995;18(5):285–290. https://doi.org/10.1002/clc.4960180512
  28. O'Brien J, Rockwood R, Suh K. Haloperidol-induced torsade de pointes. Ann Pharmacother. 1999;33(10):1046–1050. https://doi.org/10.1345/aph.19017
  29. Волков В.П. Внезапная смерть больных шизофренией. Верхневолжск. мед. журн. 2009;7(2):3–7. [Volkov V.P. Vnezapnaya smert' bol'nykh shizofreniei. Verkhnevolzhsk. med. zhurn. 2009;7(2):3–7. (In Russ.).]
  30. DA issues public health advisory for antipsychotic drugs used for treatment of behavioral disorders in elderly patients (FDA talk Paper). Rochvill (MD): US Food and Drug Adminstration; 2006.
  31. Herxheimer A, Healy D. Arrythmias and sudden death in patients taking antipsychotic drugs. Br Med J. 2002;325:1253–1254. https://doi.org://10.1136/bmj.325.7375.1253
  32. Мазур Н.А. Внезапная смерть больных ишемической болезнью сердца. Издательство Медицина; 1985. [Mazur N.A. Vnezapnaya smert' bol'nykh ishemicheskoi bolezn'yu serdtsa. Izdatel'stvo Meditsina; 1985. (In Russ.).]
  33. Silver H, Kogan H, Zlotogorski D. Postural hypotension in chronically medicated schizophrenics. J Clin Psychiatry. 1990;51(11):459-462. PMID: 1977739
  34. Akın S, Bahat G, Tufan F et al. Olanzapine as a cause of peripheric edema in an elderly man. Aging Clinical and Experimental Research. 2013;25(1):115–117. https://doi.org//10.1007/s40520-013-0002-4
  35. Hwang JP, Yang CH, Yu HC et al. The efficacy and safety of risperidone for the treatment of geriatric psychosis. J Clin Psychopharmacol. 2001;21(6):583–587. https://doi.org/10.1177/0269881105056669
  36. Durst R, Raskin S, Katz G et al. Pedal edema associated with clozapine use. IMAJ. 2000;2:485–486. PMID: 10897248
  37. Ng B, Postlethwaite A, Rollnik J. Peripheral oedema in patients taking olanzapine. Int Clin Psychopharmacol. 2003;18:57–59. https://doi.org/10.1097/00004850-200301000-00010
  38. Rozzini L, Ghianda D, Vicini Chilovi B et al. Peripheral Oedema Related to Quetiapine Therapy. Drugs & Aging. 2005;22(2):183–184. https://doi.org//10.2165/00002512-200522020- 00007
  39. Bouman WP, Pinner G. Use of atypical antipsychotic drugs in old age psychiatry. Advances in psychiatric treatment. 2002;8:49-58. https://doi.org/10.1192/apt.8.1.49
  40. Колыхалов И.В. Лечение поведенческих и психотических симптомов деменции во внебольничных условиях. Методические рекомендации. Издательство: Научный центр психического здоровья; 2012. [Kolykhalov I.V. Lechenie povedencheskikh i psikhoticheskikh simptomov dementsii vo vnebol'nichnykh usloviyakh. Metodicheskie rekomendatsii. Izdatel'stvo: Nauchnyi tsentr psikhicheskogo zdorov'ya; 2012. (In Russ.).]
  41. Jeste DV, Caligiuri MP, Paulsen JS et al. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients. Arch. Gen. Psychiatry. 1995;52:756-765. https://doi.org/10.1001/archpsyc.1995.03950210050010
  42. Jeste DV, Finkel SI. Psychosis of Alzheimer’s disease and related dementias. Diagnostic criteria for a distinct syndrome. American Journal of Geriatric Psychiatry. 2000;8:29–34. https://doi.org/10.1097/00019442-200002000-00004
  43. Lee PE, Sykora K, Gill SS et al. Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. J Am Geriatr Soc. 2005;53:1374–1379. https://doi.org//10.1111/j.1532-5415.2005.53418.x
  44. Vasilyeva I, Biscontri RG, Enns MW et al. Movement disorders in elderly users of risperidone and first generation antipsychotic agents: a Canadian population-based study. PLoS ONE. 2013; 8(5):64217. https://doi.org//10.1371/journal.pone.0064217
  45. Мосолов С.Н. Современная антипсихотическая фрамакотерапия шизофрении. РМЖ. 2004;10:646-652. [Mosolov S.N. Sovremennaya antipsikhoticheskaya framakoterapiya shizofrenii. RMZh. 2004;10:646-652. (In Russ.).]
  46. Ray WA, Griffin MR, Schaffner W et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med. 1987;316 (7):363-369. https://doi.org//10.1056/NEJM198702123160702
  47. Vestergaard P, Rejnmark L, Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int. 2006;17(6):807–816. https://doi.org//10.1007/s00198-005-0065-y
  48. Pouwels S, van Staa TP, Egberts AC et al. Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 2009;20(9):1499–1506. https://doi.org//10.1007/s00198-008-0826-5

  1. Sоrensen HJ, Jensen SO, Nielsen J. Schizophrenia, antipsychotics and risk of hip fracture: a population-based analysis. Eur Neuropsychopharmacol. 2013;23(8):872–878. https://doi.org//10.1016/j.euroneuro.2013.04.002
  2. Jalbert JJ, Eaton CB, Miller SC, Lapane KL. Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia. J Am Med Dir Assoc. 2010;11(2):120–127. https://doi.org//10.1016/j.jamda.2009.10.001
  3. Pratt N, Roughead EE, Ramsay E et al. Risk of hospitalization for hip fracture and pneumonia associated with antipsychotic prescribing in the elderly: a self-controlled case-series analysis in an Australian health care claims database. Drug Saf. 2011;34(7):567–575. https://doi.org//10.2165/00128415-201113630-00003
  4. Wang M, Hou R, Jian J et al. Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study. Hum Psychopharmacol 2014;29(2):183–189. https://doi.org//10.1002/hup.2387
  5. Takahashi T. Uchida H. John M et al. The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: findings from a longitudinal observational cohort. Schizophr Res. 2013;147(2–3):383–386. https://doi.org//10.1016/j.schres.2013.04.015
  6. Okita K, Kanahara N, Nishimura M et al. Second-generation antipsychotics and bone turnover in schizophrenia. Schizophr Res. 2014;157(1–3):137–141. https://doi.org//10.1016/j.schres.2014.05.009
  7. Davis JM, Ramsden CE. Do antipsychotics cause hip fractures? Promise and pitfalls of big data. Journal of Clinical Psychiatry. 2015;76(9):1155-1156. https://doi.org//10.4088/JCP.14com09551
  8. Huybrechts KF, Rothman KJ, Silliman RA et al. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ. 2011;183(7):411–419. https://doi.org//10.1503/cmaj.101406
  9. Knol W, van Marum RJ, Jansen PA et al. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc. 2008;56(4):661–666. https://doi.org//10.1111/j.1532- 5415.2007.01625.x
  10. Trifirо G, Gambassi G, Sen EF et al. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study. Ann Intern Med. 2010;152(7):418–425. https://doi.org//10.7326/0003-4819-152-7-201004060-00006
  11. Herzig SJ, LaSalvia MT, Naidus E et al. Antipsychotics and the Risk of Aspiration Pneumonia in Individuals Hospitalized for Nonpsychiatric Conditions: A Cohort Study. J Am Geriatr Soc. 2017;12(65):2580-2586. https://doi.org//10.1111/jgs.15066

  1. Tan L, Tan L, Wang HF et al. Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysis Alzheimer's Research & Therapy. 2015;7:20. https://doi.org//10.1186/s13195-015-0102-9

Рекомендуемая литература:

Остроумова О.Д. , Голобородова И.В., Исаев Р.И., Переверзев А.П., Антипсихотики: особенности нежелательных побочных реакций у лиц пожилого и старческого возраста. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(2): 105-117.

DOI: 10.17116/jnevro2019119021105